Kartagener Syndrome
14
3
4
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (14)
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia
The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)
Swiss Primary Ciliary Dyskinesia Registry
International Primary Ciliary Dyskinesia Cohort
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
Physical Fitness, Exercise Capacity and Activities of Daily Living in Primary Ciliary Dyskinesia: a Retrospective Study
Genetics of Primary Ciliary Dyskinesia
Rare Genetic Disorders of the Breathing Airways
Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia
Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease
Dyskinesia, Heterotaxy and Congenital Heart Disease
Diagnosis of Primary Ciliary Dyskinesia